Rigel Pharmaceuticals Inc. Q3 Loss decreases, beats estimates

Rigel Pharmaceuticals Inc. (RIGL) released Loss for third quarter that decreased from the same period last year and beat the Street estimates.

The company's bottom line came in at -$19.04 million, or -$0.11 per share. This compares with -$20.95 million, or -$0.12 per share, in last year's third quarter.

Analysts on average had expected the company to earn -$0.13 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter rose 4.0% to $22.41 billion from $21.54 billion last year.

Rigel Pharmaceuticals Inc. earnings at a glance (GAAP) :

-Earnings (Q3): -$19.04 Mln. vs. -$20.95 Mln. last year.
-EPS (Q3): -$0.11 vs. -$0.12 last year.
-Analyst Estimates: -$0.13
-Revenue (Q3): $22.41 Bln vs. $21.54 Bln last year.

For comments and feedback contact: editorial@rttnews.com

Follow RTT